Mathilde Serres
Analista di Private Equity presso Turenne Capital Partenaires SA
Provenienza dei contatti di primo grado di Mathilde Serres
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Turenne Capital Partenaires SA
Turenne Capital Partenaires SA Investment ManagersFinance Turenne Capital Partenaires SA (Turenne Capital) is a venture capital subsidiary of Turenne Associés SA founded in 1999 by Aymard de Lasteyrie. The firm is headquartered in Paris, France.
43
| Subsidiary | Investment Managers | 43 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Mathilde Serres tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
ALTRAN TECHNOLOGIES | Miscellaneous Commercial Services | Corporate Officer/Principal | |
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Director/Board Member | |
TIGENIX NV | Medical Specialties | Director/Board Member | |
KIORA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
EUROGERM SA | Food: Specialty/Candy | Director/Board Member | |
Innovacom Gestion SAS
Innovacom Gestion SAS Investment ManagersFinance Innovacom Gestion SAS (Innovacom) is a venture capital firm founded in 1988 and a subsidiary of Turenne Capital Partenaires. Innovacom is headquartered in Paris, France with additional offices in Stockholm and San Francisco. | Investment Managers | Private Equity Analyst | |
VALEO | Auto Parts: OEM | Chief Tech/Sci/R&D Officer | |
Evolem SAS
Evolem SAS Investment ManagersFinance Evolem SAS (Evolem) is a private equity and venture capital subsidiary of Bruno Rousset SAS founded in 1996 by Bruno Rousset. The firm is headquartered in France. | Investment Managers | Private Equity Analyst | |
Sofimac Innovation SAS
Sofimac Innovation SAS Investment ManagersFinance Sofimac Innovation SAS is an independent, early-stage venture capital firm which was created in 1998 by Eric Harlé and Didier Moret. Headquartered in Paris, France, Sofimac Innovation manages venture capital funds which provide equity financing for start-ups and early-stage companies in the Information and Communication Technologies (Software, SaaS, Multimedia and Telecom) sector. | Investment Managers | Private Equity Investor Private Equity Investor | |
Ventech SA
Ventech SA Investment ManagersFinance Ventech SA is part of the venture capital arm and a wholly-owned subsidiary of Natixis Private Equity (NPE), which in turn is a subsidiary of Paris-based Natixis SA (XP: KN). Ventech was established in 1998 and is located in Paris. The firm specializes in technology venture capital investing. Ventech manages venture capital funds for a clientele of European institutional investors, with NPE as their sponsor. The firm relies on international strategic alliances with seeding funds and venture capital firms in Germany, Switzerland, Israel, Japan and the US. | Investment Managers | Private Equity Investor | |
Abénex Capital SAS
Abénex Capital SAS Investment ManagersFinance Abénex Capital SAS is an Independent Private Equity firm founded in 1957 by Hervé Claquin. Abénex Capital is headquartered in Paris. | Investment Managers | Private Equity Analyst | |
SCYNEXIS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Naxicap Partners SA
Naxicap Partners SA Investment ManagersFinance Naxicap Partners SA operates as a private equity firm. It invests in hospitals, pharmaceuticals, business services, information technology, textile, and consumer goods sectors. The company was founded in 1995 and is headquartered in Paris, France. | Investment Managers | Chief Investment Officer Private Equity Analyst | |
Paluel-Marmont Capital SA
Paluel-Marmont Capital SA Investment ManagersFinance Paluel-Marmont Capital SA (PMC) is the wholly-owned private equity subsidiary of Compagnie Lebon (XP: LBON) in France. Formerly known as Lebon Développement, the firm was established in 1991. Located in Paris, PMC invests their own equity in leveraged buy-outs in small- and mid-size businesses, sharing their professional expertise and business network with investee company management. | Investment Managers | Director/Board Member | |
XAnge Private Equity SA
XAnge Private Equity SA Investment ManagersFinance XAnge Private Equity SA (XAnge Private Equity) is a private equity portfolio management firm which was created in 2003 by La Poste and ABN AMRO and is headquartered in France. | Investment Managers | Private Equity Investor | |
National Aeronautics & Space Administration | General Government | Corporate Officer/Principal | |
Université Paris 1 Panthéon-Sorbonne | College/University | Graduate Degree Masters Business Admin | |
Institut National de la Santé & de la Recherche Médicale
Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France. | Miscellaneous Commercial Services | Director/Board Member | |
Université Paris Dauphine-PSL | College/University | Graduate Degree Undergraduate Degree | |
École Centrale Paris | College/University | Undergraduate Degree | |
École des Hautes Études Commerciales de Paris | College/University | Masters Business Admin Undergraduate Degree | |
Institut d'Optique Graduate School | College/University | Undergraduate Degree | |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member | |
ALTUR INVESTISSEMENT | Investment Managers | Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Chief Investment Officer | |
A Plus Finance SA
A Plus Finance SA Investment ManagersFinance A Plus Finance SA (A Plus Finance) is a private equity firm. The firm is founded in 1998 by Niels Court Payen andFrédéric Bayol. The firm headquartered in Paris, France. | Investment Managers | Private Equity Analyst | |
Siparex XAnge Venture SAS
Siparex XAnge Venture SAS Investment ManagersFinance Siparex XAnge Venture SAS is an Independent Venture Capital firm founded in 1977 by Benjamin Teszner. Siparex XAnge Venture SAS is headquartered in Paris. | Investment Managers | Director/Board Member Private Equity Analyst | |
M Capital Partners SASU
M Capital Partners SASU Investment ManagersFinance M Capital Partners SASU is an Independent Private Equity firm founded in 2001 by Rudy Secco. M Capital Partners SASU is headquartered in Toulouse. | Investment Managers | Private Equity Investor | |
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director/Board Member | |
Eye Tech Care SA
Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | Medical Specialties | Director/Board Member | |
Covagen AG
Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Biotechnology | Director/Board Member | |
MW Gestion SA
MW Gestion SA Investment ManagersFinance MW Gestion SA is an independent financial asset management firm headquartered in Paris, France. The firm was founded in 1992 and offers UCITS funds and discretionary mandates, specialized in share and bond investments to individuals and institutional clients. | Investment Managers | Director/Board Member | |
Renaissance Corporate SAS | Investment Managers | President President | |
Nord Capital Partenaires SAS | Investment Managers | Chief Executive Officer Chief Executive Officer Director/Board Member Private Equity Investor | |
Dzeta Conseil SASU
Dzeta Conseil SASU Investment ManagersFinance Dzeta Conseil SASU (Dzeta Conseil) is an independent private equity firm headquartered in Paris, France. It was founded in 2009 by Claude Harmon. | Investment Managers | Private Equity Investor | |
Germitec SA
Germitec SA Medical SpecialtiesHealth Technology Germitec SA engages in the research, design, and marketing of medical hygiene systems. It develops Antigermix, which is used in disinfecting heat-sensitive medical instruments. The company was founded in 2005 and is headquartered in Ivry-sur-Seine, France. | Medical Specialties | Director/Board Member | |
NOTE INC. | Internet Software/Services | Director/Board Member | |
Extens SAS
Extens SAS Investment ManagersFinance Extens SAS (Extens) is an independent venture capital firm headquartered in Paris, France. The firm was founded by Arnaud Houette and Quentin Jacomet in 2013. | Investment Managers | Private Equity Investor | |
Essling Capital SAS
Essling Capital SAS Investment ManagersFinance Essling Capital SAS (Essling Capital) is an independent private equity firm founded in 2016 by Frank-Noël Vandenberghe. The firm is headquartered in Paris, France. | Investment Managers | Private Equity Investor Private Equity Analyst Private Equity Investor | |
Geneo Capital Entrepreneur SA
Geneo Capital Entrepreneur SA Investment ManagersFinance Geneo Capital Entrepreneur SA is an Independent Private Equity/Venture Capital firm founded in 2018 by Fanny Letier. Geneo Capital Entrepreneur SA is headquartered in Neuilly-sur-Seine. | Investment Managers | Private Equity Investor | |
Jeito Capital SASU
Jeito Capital SASU Investment ManagersFinance Jeito Capital SASU (Jeito Capital) is an Independent Venture Capital firm founded in 2018 by Rafaele Tordjman and headquartered in Paris, France. | Investment Managers | Private Equity Investor | |
Mablink Bioscience
Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | Pharmaceuticals: Major | Director/Board Member |
Statistiche
Distribuzione geografica
Francia | 38 |
Stati Uniti | 6 |
Belgio | 3 |
Regno Unito | 3 |
Spagna | 2 |
Settori
Finance | 22 |
Health Technology | 16 |
Consumer Services | 7 |
Commercial Services | 4 |
Consumer Non-Durables | 2 |
Posizioni
Director/Board Member | 63 |
Private Equity Investor | 50 |
Private Equity Analyst | 22 |
Corporate Officer/Principal | 21 |
Chairman | 13 |
Contatti più connessi
Insiders | |
---|---|
Mounia Chaoui-Roulleau | 27 |
François Lombard | 19 |
Christian Maugey | 14 |
Olivier Motte | 14 |
Julie Rachline | 13 |
Benoît Pastour | 10 |
Hubert Michalowski | 8 |
François Picarle | 8 |
Marie Desportes | 6 |
Marine Bussienne | 4 |
Anne-Sophie Maes | 4 |
Bervin Bouani | 4 |
Charles Bourgain | 3 |
Christophe Deldycke | 3 |
Nam Metzger | 3 |
- Borsa valori
- Insiders
- Mathilde Serres
- Connessioni Società